Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,029 across all filing types
Latest filing 2021-02-18 Director's Dealing
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Director's Dealing 2021
Director's Dealing
2021-02-18 English
Director's Dealing 2021
Director's Dealing
2021-02-18 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the registration of securities for resale by selling stockholders, including the number of shares, warrants, and related terms. The document is a registration statement used for capital raising and securities offering purposes, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration filing itself. Therefore, it fits the category of Capital/Financing Update filings, which cover company fundraising and capital structure changes.
2021-02-17 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the closing of a previously announced registered direct offering and includes a press release as an exhibit. There are no detailed financial statements or comprehensive financial analysis present, only an announcement of a financing event. The document length is 3099 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2021-02-12 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 9, 2021, by Enveric Biosciences, Inc. It reports the entry into a material definitive agreement related to a securities purchase agreement and a registered direct offering, including details about the issuance of common stock and warrants. The document includes descriptions of the agreements, terms of the offering, and related exhibits such as the purchase agreement and legal opinion. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising transaction and related agreements, which fits the definition of a Capital/Financing Update. The document length is sufficient and contains substantive information about the financing event, not merely an announcement or a certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-02-11 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by Enveric Biosciences Inc. It details the offering of common stock and warrants, pricing, advisory fees, and related terms. The document includes references to the Securities Act of 1933 and SEC registration numbers, and it is clearly a disclosure document for a capital raising event. It is not a financial report, earnings release, or management discussion, but rather a detailed offering document for new securities issuance. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length (15,000 characters) and content confirm it is the actual offering document, not just an announcement or a brief summary. Therefore, the correct classification is CAP with high confidence.
2021-02-11 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.